PMON165 Favorable Liver Safety Profile of the Selective Glucocorticoid Receptor Modulator Relacorilant in Healthy and Hepatically Impaired Adults and in Patients with Cushing Syndrome

BACKGROUND: Relacorilant is a highly selective glucocorticoid receptor (GR) modulator in development for the treatment of endogenous Cushing syndrome (CS). Unlike the FDA-approved GR antagonist mifepristone, relacorilant lacks affinity for the progesterone and other receptors. In a phase 2 study in...

Descripción completa

Detalles Bibliográficos
Autores principales: Moraitis, Andreas, Custodio, Joseph M, Tudor, Iulia Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627723/
http://dx.doi.org/10.1210/jendso/bvac150.1137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627723/
http://dx.doi.org/10.1210/jendso/bvac150.1137

Ejemplares similares